Prognostic significance of TMEM131L in glioma and establishment of oxidative stress prognostic model

Abstract

Gliomas are the most aggressive of all brain tumors. In this study, it was found that there is a significant expression of transmembrane-like 131 (TMEM131L) in glioma tissues. The relevance of TMEM131L in the diagnosis and clinical prognosis of GBM and LGG was verified by additional clinical correlation and survival analysis. The area under the curve (AUC) of the receiver operating characteristic (ROC) curve reflected the diagnostic effect of TMEM131L on the clinicopathologic features of glioma. As a unique molecular marker for the poor prognosis of overall survival (OS), PFI, and DSS in patients with GCB and LGG, TMEM131L might be employed, according to time-dependent ROC curves and Kaplan–Meier survival analysis at 1, 3, and 5 years. The potential methylation sites of TMEM131L were selected by correlation analysis between TMEM131L and DNA methylation sites. Meanwhile, TMEM131L was significantly correlated with matrix, immunity, and estimated scores of GBM and LGG. The CIBERSORT analysis revealed a significant correlation between immune checkpoint and infiltration of 22 different kinds of immune cells. Coexpression genes of TMEM131L associated with oxidative stress phenotype were screened by the LASSO logistic regression analysis. Nomogram and calibration curves further confirmed that the prognostic model composed of SYT1, CREB3L3, ITPR1, RASGRF2, PDX1, and RASGRF1 has good stability and potential application value for poor prognosis in patients with glioma.

Proteomic and metabolomic analyses illustrate the mechanisms of expression of the O6‐methylguanine‐DNA methyltransferase gene in glioblastoma

“…Integrated metabolomics and proteomics analysis was performed, and six key proteins, DENN domain containing 3, Ras protein‐specific guanine nucleotide releasing Factor 2 (RasGRF2), potassium voltage‐gated channel subfamily Q member 2, sprouty RTK signaling antagonist 2, unc‐5 netrin receptor C and glutathione S‐transferase alpha 1, were identified in the MGMT group and GBM group. Moreover, Shan et al, 39 have pointed that RasGRF2 has good stability and potential application value for poor prognosis in patients with glioma. Then, three key pathways, including the synthesis and degradation of ketone bodies, glycerophospholipid metabolism and fatty acid degradation, were recognized as potential biomarkers for recognizing MGMT promoter unmethylated GBM and MGMT promoter methylation positive GBM from GBM patient samples, with areas under the curve of 0.7895, 0.7326 and 0.7026, respectively.…”

Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives

“…Identifying various distributed genes in GBM establishes a valuable reference database for researchers, offering insights into potential therapeutic targets. Table 2 presents the current GBM genes, biological targets, and immune-related targets [ 17 , 47 , 56 , 60 , 69 , 97 – 240 ]. So, characterizing the transcriptome of GBM has yielded profound insights into the highly variable transcriptomic features of GBM and its microenvironmental cell components.…”